YOLFTbeta
Indivior PLC Ordinary Shares

Indivior PLC Ordinary Shares

INDV · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

26.74USD-1.47 (-5.21%)

Price History

Full chart

Market Stats

Previous Close28.21
Open28.29
Day Range26.52 – 28.79
52-Week Range22.56 – 42.81
Volume6.08M
Market Cap4.35B
P/E (TTM)13.22
Forward P/E9.46
EPS2.79
Dividend Yield0.00%
Beta1.11
50-Day Avg37.16
200-Day Avg35.72

About

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Joseph J. Ciaffoni
  • Employees827
  • Headquarters10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235, USA
  • Websitehttps://www.indivior.com

Leadership

  • Mr. Joseph J. CiaffoniCEO & Director · b. 1971
  • Mr. Ryan PreblickChief Financial Officer · b. 1976
  • Dr. Christian HeidbrederChief Scientific Officer · b. 1963
  • Mr. Jeffrey W. Burris J.D.Chief Legal Officer · b. 1972
  • Mr. Patrick a. BarryChief Commercial Officer · b. 1968
  • Mr. Jason ThompsonVice President of Investor Relations
  • Mr. Kevin L. EspinozaChief Integrity & Compliance Officer
  • Ms. Angela Colon-Mahoney M.S.Chief Human Resources Officer · b. 1976
  • Ms. Vanessa ProcterExecutive Vice President of Corporate Affairs
  • Dr. Ann Wheeler Pharm.D.Chief Medical Officer

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue968.89M1.15B959.92M785.00M647.00M791.00M901.00M1.09B1.19B1.24B
Growth (%)-+18.50%-16.39%-18.22%-17.58%+22.26%+13.91%+21.31%+8.69%+4.29%
Cost of Revenue110.81M122.90M134.68M140.00M97.00M127.00M151.00M174.00M231.00M246.00M
Gross Profit858.08M1.03B825.25M645.00M550.00M664.00M750.00M919.00M957.00M993.00M
Gross Margin88.56%89.30%85.97%82.17%85.01%83.94%83.24%84.08%80.56%80.15%
Operating Expense520.16M601.89M508.14M467.00M706.00M451.00M831.00M1.07B925.00M728.00M
Operating Income337.92M423.32M317.11M178.00M-156.00M213.00M-81.00M-156.00M32.00M265.00M
Operating Margin34.88%36.87%33.03%22.68%-24.11%26.93%-8.99%-14.27%2.69%21.39%
EBITDA149.27M436.97M310.42M230.00M-123.00M238.00M-46.00M-99.00M84.00M304.00M
EBITDA Margin15.41%38.06%32.34%29.30%-19.01%30.09%-5.11%-9.06%7.07%24.54%
Net Income32.05M60.92M262.67M134.00M-148.00M205.00M-44.00M-129.00M2.00M210.00M
Net Income Margin3.31%5.31%27.36%17.07%-22.87%25.92%-4.88%-11.80%0.17%16.95%
R&D108.98M93.49M63.99M53.00M40.00M52.00M74.00M116.00M107.00M97.00M
R&D as % of Total Revenue11.25%8.14%6.67%6.75%6.18%6.57%8.21%10.61%9.01%7.83%
Interest Expense51.00M49.00M31.00M22.00M24.00M26.00M29.00M35.00M41.00M45.00M
Interest Expense % of Total Revenue5.26%4.27%3.23%2.80%3.71%3.29%3.22%3.20%3.45%3.63%

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.21B1.44B1.55B1.65B1.53B1.83B1.78B1.76B1.32B1.20B
Total Liabilities1.50B1.65B1.48B1.44B1.45B1.63B1.73B1.96B1.67B1.30B
Total Equity-295.00M-203.00M66.00M209.00M82.00M203.00M51.28M-191.00M-348.00M-98.00M
Cash692.00M863.00M924.00M1.06B858.00M1.10B778.18M316.00M319.00M195.00M
Total Debt535.00M482.00M241.00M293.00M285.00M286.00M277.00M283.00M375.00M351.00M
Net Debt-157.00M-381.00M-683.00M-767.00M-573.00M-816.00M-501.18M-33.00M56.00M156.00M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow407.00M295.00M303.00M151.00M-193.00M353.00M-4.00M-300.00M36.00M-27.00M
Investing Cash Flow-35.00M-43.00M-4.00M-2.00M-4.00M-14.00M-222.00M-95.00M69.00M-66.00M
Financing Cash Flow-147.00M-84.00M-237.00M-13.00M-10.00M-94.00M-101.00M-64.00M-102.00M-30.00M
Capital Expenditure35.00M43.00M41.00M7.00M4.00M34.00M5.00M53.00M31.00M67.00M
Free Cash Flow372.00M252.00M262.00M144.00M-197.00M319.00M-9.00M-353.00M5.00M-94.00M
Dividends Paid69.00M---------
FCF to OCF91.40%85.42%86.47%95.36%102.07%90.37%225.00%117.67%13.89%348.15%
Dividend Paid to FCF18.55%---------

Earnings

Report DateMay 5, 2015Jul 29, 2015Nov 3, 2015Feb 18, 2016May 3, 2016Jul 29, 2016Nov 2, 2016Feb 22, 2017May 3, 2017Jul 27, 2017Nov 2, 2017Feb 15, 2018May 2, 2018Jul 25, 2018Nov 1, 2018Feb 14, 2019May 2, 2019Jul 31, 2019Oct 31, 2019Feb 13, 2020May 14, 2020Jul 30, 2020Oct 29, 2020Feb 18, 2021Apr 29, 2021Jul 29, 2021Oct 28, 2021Feb 16, 2022Apr 28, 2022Jul 28, 2022Oct 27, 2022Feb 16, 2023Apr 27, 2023Jul 27, 2023Nov 9, 2023Feb 22, 2024Apr 25, 2024Jul 25, 2024Oct 24, 2024Feb 20, 2025Apr 24, 2025Jul 31, 2025Oct 30, 2025Feb 26, 2026Apr 30, 2026Aug 3, 2026Oct 29, 2026
EPS Estimate---0.20-0.340.270.35---------0.500.30-0.25-1.100.100.100.150.250.300.150.150.300.300.290.270.400.220.300.280.420.400.310.260.230.250.410.650.660.970.93
EPS Actual0.530.450.330.350.340.550.500.350.530.510.35-1.000.620.450.610.160.440.500.30-0.38-1.110.100.05-0.090.510.400.150.250.280.340.28-1.340.400.390.340.430.370.440.030.320.410.510.720.820.961.15-
Surprise---75.00%-61.76%85.19%0.00%---------0.00%0.00%-50.52%-1.22%0.00%-50.00%-159.07%104.76%33.33%0.00%66.07%-8.27%14.53%-3.45%-596.59%0.00%77.27%13.33%53.57%-11.90%10.00%-90.32%22.65%78.26%104.00%75.61%26.15%45.45%18.56%-
Timing---Pre-market-Pre-marketPre-marketPre-market-------------------------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap4.35B
Enterprise Value4.52B
Trailing P/E13.22
Forward P/E9.46
Price / Sales3.27
Price / Book145.25
EPS2.79
Book Value-1.76
Revenue (TTM)1.33B
Gross Profit (TTM)1.14B
EBITDA576.00M
Profit Margin26.75%
Operating Margin46.94%
Return on Equity12.20%
Return on Assets26.40%
Shares Outstanding118.03M
Shares Float115.80M
Beta1.11
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 49.00
  • Strong Buy
    5
  • Buy
    2

Ownership Breakdown

Institutions
99.12%
Insiders
1.82%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    18.54M14.83%
  • Vanguard Portfolio Management, LLC
    7.89M6.31%
  • Oaktree Capital Management LLC
    6.98M5.59%
  • Vanguard Capital Management, LLC
    5.59M4.47%
  • State Street Corp
    4.90M3.92%
  • Two Seas Capital LP
    4.75M3.80%
  • Fuller & Thaler Asset Management Inc
    4.53M3.62%
  • Madison Avenue Partners, LP
    4.32M3.45%
  • Morgan Stanley - Brokerage Accounts
    3.51M2.80%
  • Deerfield Management Co
    3.10M2.48%
  • Geode Capital Management, LLC
    2.93M2.34%
  • Mangrove Partners
    2.74M2.19%
  • Citadel Advisors Llc
    2.67M2.13%
  • The Goldman Sachs Group Inc
    2.41M1.93%
  • Arrowstreet Capital Limited Partnership
    2.32M1.86%
  • UBS Group AG
    2.19M1.75%

Top Fund Holders

  • iShares Core S&P Small-Cap ETF
    7.43M5.94%
  • Vanguard MStar Total Stk Mkt Idx Invest
    3.88M3.11%
  • iShares Russell 2000 ETF
    3.06M2.45%
  • Vanguard Small Cap Index
    2.81M2.24%

Dividends

20261×
8.13Nov 3, 2026
20161×
0.47Jun 16, 2016
20151×
0.16Sep 17, 2015

Stock Splits

  • Oct 10, 20221:5